Get started
Work

Supplementary Information from Efficacy and Safety of the Anti–PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study

Year: 2023
Type: supplementary-materials
Abstract: Research Protocol for the Phase I Clinical Study of the Recombinant Fully Human Anti-PD-L1 Monoclonal Antibody Socazolimab
DOI: 10.1158/1078-0432.22488348
Authors: Jusheng An, Jie Tang, Benjamin X. Li, Huihua Xiong, Hui Qiu, Lin Luo, Li Wang, Danbo Wang, Qi Zhou, Qin Xu, Honglin Song, Yunyan Zhang, Hongping Zhang, Yujie Li, Xiaohui Yu, Jing Zhang, Rachel Ng, Wayne Zhao, Michael Wong, Xiangrong Dai, Guiling Li, Lingying Wu
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
OpenAlex ID: W4361962829
Cites: 4
Cited by:
Related to: 10